gamma-tert-butyl methotrexate has been researched along with trimetrexate in 1 studies
*Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect. [MeSH]
*Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cucchi, CA; Flatow, J; Frei, E; Rosowsky, A; Wright, JE | 1 |
1 other study(ies) available for gamma-tert-butyl methotrexate and trimetrexate
| Article | Year |
|---|---|
Methotrexate and gamma-tert-butyl methotrexate transport in CEM and CEM/MTX human leukemic lymphoblasts.
Topics: Cell Line; Drug Resistance; Humans; Kinetics; Leukemia, Lymphoid; Methotrexate; Tetrahydrofolate Dehydrogenase; Trimetrexate | 1993 |